PROTEIN aggregation is one of the consequences of cellular events. Their accumulation is related to neuronal degeneration and organ failure 1 . Alzheimer's disease (AD) is an irreversible degeneration of the brain that causes dementia followed by cognition impairment and loss of memory. The impairment of cognition in human brain is caused by deposition of the aggregates of β-amyloid (Aβ) peptide in a progressive manner since the initiation of the process 2 . Even the soluble oligomers of Aβ peptide are cytotoxic to neuronal cells. It is unclear how the equilibration between the free, nonpathogenic monomeric peptides and the oligomers that are forerunners of the aggregate is disturbed 3 . As of today, no natural product or synthetic compound has been discovered as a drug to prevent or cure AD.
Pineapple (Ananas comosus) is a medicinal plant. All parts of the plant contain high level of protease activity. The plant extracts are collectively known as bromelain. Medicinal properties of bromelain are brought about synergistically by an array of enzymes present in it 4 . Stem bromelain, the major cysteine protease of the extract from pineapple stem, is commercially available 5 . Bromelain has broad specificity towards hydrolysis of peptide bonds and offers a wide range of therapeutic activities [6] [7] [8] [9] . Due to its efficiency after oral administration, safety and lack of undesired side effects, bromelain is being increasingly considered as a phyto-therapeutical drug 7, 10 . In recent years, the role of proteases in the pathogenesis, diagnosis and treatment of amyloid peptide-related diseases has been extensively studied 11, 12 . Generally, amyloid fibrils are stable, rich in β-sheet content and are resistant to proteases 13 . However, this notion is not universally valid. Cathepsin B, a lysosomal cysteine protease, plays a crucial role in intracellular proteolysis. Upregulation of this enzyme is observed in a number of clinical conditions. Anti-amiloidogenic and related neuroprotective function of cathepsin B against Aβ peptides has been reported 14 . Subsequently, cystatin C, a cysteine protease inhibitor that inactivates cathepsin B, has further confirmed the role of the latter in regulating the formation of Aβ aggregate. In humans, all cells containing nucleus produce cystatin C and it is available essentially in all body fluids and tissues. Formation of cathepsin B-cystatin C conjugate causes upregulation of Aβ aggregate and AD 15 . Currently, the regulatory roles of proteases in the biosynthetic pathway of Aβ peptide and formation of corresponding aggregate from the monomeric peptide are well established 16 . With further advancement of information, the role of this class of cysteine proteases in AD has been fairly confirmed 17 . During studies on stem bromelain, we observed that it can destabilize Aβ-aggregate 18 . It may originate from direct proteolysis of the aggregate. Alternately, a pool of peptides that are generated arising from 'auto-digestion' of bromelain may be the causative agent. These peptides may act as potent molecules to interact with the aggregates leading to their disintegration to near-monomeric state. To distinguish this, inactive bromelain devoid of proteolytic activity was prepared. This nonfunctional molecule can also destabilize the aggregates. Therefore, the role of amino acid stretches of bromelain in the process of destabilization is suggestive 18 . Of course, this does not exclude proteolysis of amyloid aggregates by bromelain itself. Here, we present that small peptides generated from bromelain after protease digestion as par human digestive system show potent destabilization of Aβ-aggregates. Small synthetic peptides, the sequences of which have been derived from the template of bromelain, also show destabilization of Aβ-aggregates.
Fine chemicals were procured as follows: carboxypeptidase (bovine pancreas), α-chymotrypsin (bovine pancreas), elastase (porcine pancreas), Sephadex G-50 and G-10, stem bromelain (E.C. 3. 19 . Protein components of commercially available stem bromelain were separated using size-exclusion chromatography 18 . Stem bromelain (10 mg/ml) was suspended in 10 mM Na-phosphate, pH 7.5 (buffer A) at 4°C for 16 h. After centrifugation at 8000 g for 15 min, 2.5 ml of the supernatant was applied onto a Sephadex G-50 column (1.5 × 90 cm) equilibrated with buffer A. The chromatogram separated the components into two fractions. Protease activity that was confined to the first fraction was pooled. The second fraction contained the pigments, small peptides and unidentified small molecules. The protein fraction showed single band in 10% PAGE at pH 7.5 and zymography using bovine serum albumin as substrate 20 . Proteolytic activity was measured using azocasein as substrate 21 .
Formation of β-amyloid peptide of amino acid length In the fluorimetric estimation of aggregate formation, thioflavin T (ThT) assay was performed. ThT (10 μl, 250 μM in water, ε 412 nm = 35,000 M -1 cm -1 , ex: 450 nm; em: 480-600 nm) was added to Aβ40/42 aggregate (10 μM) and the volume was made up to 1 ml by buffer A containing 100 mM NaCl 22 . To follow the time course of disaggregation, Aβ40/42 aggregates (10 μM) were incubated in presence of 0.01-10 μM of bromelain-derived peptides at 37°C for 15 days. Aliquots were withdrawn at an interval of 3 days and disaggregation was followed from ThT assay. Bromelain-derived peptide solution in the absence of Aβ aggregates was also incubated under identical conditions. This served as control to follow self-aggregation of these peptides. A Hitachi F-4500 spectrofluorimeter (slit width 10/10 nm) attached with a circulating water bath was used.
For transmission electron microscope (TEM) images, test sample (10 μl) was placed on a carbon-coated 300-mesh copper grid (GSCu300C, ProSciTech, Australia) for 1 min at 25°C and the unbound substrates were removed using blotting paper. To stain the adhered particles, the grid was treated with 2% uranyl acetate for 20 s and excess reagent was removed as mentioned earlier. The grid was dried for 15 min and analysed with a TEM (model FEI TECNAI G2 Spirit BioTwin, Czech Republic) operating at an accelerating voltage of 80 kV (115,000 ×). For atomic force microscopy (AFM) images, test sample (10 μl) was placed on freshly cleaved pyrolytic graphite (HOPG) surface for 20 min and thereafter dried under vacuum. Sometimes the sample was gently washed with deionized Milli-Q water to remove unattached molecules. Acoustic AC-mode AFM was used with a Pico plus 5500 AFM (Agilent Technologies, USA) with a piezoscanner of maximum range 9 μm. A micro fabricated silicon cantilever of length 225 μm with a nominal spring force constant of 21-98 N/m was used as nanosensor. Cantilever oscillation frequency was tuned into resonance frequency of 150-300 kHz. The images (512 × 512 pixels) were captured with a scan size between 0.5 and 5 μm. Images were processed by flattening using Pico Scan software (Molecular Imaging Corporation, USA).
For mass spectrometric analysis, samples of peptides were desalted using Zip-Tip μ-C 18 column filters (Millipore, Billerica, MA, USA). Matrix-bound peptides were eluted by 50% acetonitrile containing 0.01% trifluoroacetic acid (TFA). The samples were desolvated at 100-125°C and analysed under positive mode of electrospray ionization (ESI) using a Q-Tof Mass Spectrometer (Waters Corporation, USA). Deconvolution of the raw spectra was done with MaxEnt1 algorithm. Inactive bromelain was prepared after treating the enzyme (1 mg/ml in buffer A) with 5 μM of iodoacetamide for 30 min at 25°C in the dark. Excess reagent was removed by exhaustive dialysis against buffer A. To ensure complete inactivation, modified bromelain was heated at 100°C for 5 min. Turbidity of the solution was removed by centrifugation. Proteolytic activity of this preparation was beyond detection by azocasein assay or zymography.
Proteolysis of bromelain under conditions similar to human digestive system was done as follows: bromelain (100 mg) in 2 ml of 5% formic acid (pH ~2.0) was stirred. The insoluble material was removed by centrifugation. Pepsin (2 mg, 1 : 50 wt/wt) was added to the solution and was incubated at 37°C for 4 h. Thereafter, NH 4 HCO 3 was added to increase the pH to 7.5. Trypsin and chymotrypsin (2 mg each, 1 : 50 wt/wt) along with trace amounts of elastase and carboxypeptidase (type-II PMSF-treated) were added for digestion at 37°C for 8 h. This was followed by an additional incubation with BBM proteases for 4 h. These incubation conditions were at par foods that are exposed in the human gastrointestinal tract, as far as possible.
To follow inhibition of aggregate formation, if any, Aβ40 (0.1 mg/ml) was incubated in buffer A containing 100 mM NaCl for 18 h at 37°C in the presence of 5-160 μg/ml of bromelain. Also, bromelain was either proteolytically active or inactive or auto-digested or digested by proteases as par human digestive system. All forms of bromelain were incubated under identical conditions as controls to follow self-aggregation of peptides generated from bromelain itself.
Small peptides formed after proteolysis of bromelain were separated from the undigested enzymes along with large polypeptides after passing through Sephadex G-10 SE-column (71 × 1.2 cm, fractionation range >700 Da). The column was fitted to a Bio-Logic Duo Flow instrument (Bio-Rad laboratories) under 4-6 psi pressure, equilibrated with buffer A at a flow rate of 6 ml/h. Elution of protein/ peptides was followed continuously at 220 and 280 nm using Biologic Quad Tec UV-vis detector. Fraction size was 2 ml. Peptide concentration was determined using ε 214 nm = 923 M -1 cm -1 (ref. 23 ). Mass of peptides present in each fraction was determined by mass spectrometry. Fractions containing peptides of M w < 700 Da were pooled.
Prediction of peptides from bromelain causing disaggregation of Aβ amyloids was done using bioinformatic tools. The sequence of 212 amino acid residues of bromelain and mass of small peptides generated from MS spectrum as stated above were provided as input in Interactive FindPept Analysis software. The software generated a large number of small peptide sequences corresponding to the observed masses and sequence of bromelain. Comparing the sequence of bromelain with Aβ42 using ClustalW (multiple sequence alignment) software, probable sequences of potent peptides from bromelain interacting with Aβ peptide were predicted (described in detail later in the text). This prediction was based on the assumption that peptides which have strong homology with the sticky region of Aβ peptide (residues 15-22) interact most favourably with the aggregates.
Cytotoxic effect of Aβ aggregates on human neuroblastoma cells (SH-SY5Y) was estimated from MTT assay. Cells were maintained in DMEM/Ham's F-12 (1 : 1 v/v) medium supplemented with 10% FBS, 2 mM L-glutamine, 1% penicillin/streptomycin antibiotics and 0.2% antimycotic agent. Cells were grown at 37°C in 95% air/5% CO 2 . Harvested cells were plated in 96-well polystyrene plates (Corning Inc., Corning, NY, USA) with approximately 10,000 cells/100 μl of medium/well. Plates were incubated at 37°C for 24 h to attach the cells. Aβ42 (1 μM) was pre-incubated for 24 h in the presence and absence of bromelain-derived peptides, diluted with fresh medium and added to individual wells. The same volume of medium was added to control cultures. The plates were incubated for an additional period of 48 h at 37°C. Cell viability was determined after addition of 10 μl of 5 mg/ml of MTT to each well 24 . After incubation for 4 h at 37°C, the medium was aspirated and 100 μl of DMSO was added to each well followed by agitation for 10 min. A multi-well assay plate reader (BioTek-Epoch, BioTek Instruments, Inc.) was used for measurement of A 595 nm . Cell viability was calculated by dividing the absorbance of the solutions of the wells containing test samples by the absorbance of wells containing medium alone after background correction for each. All data are expressed as mean ± SD. Significant differences of data were calculated by Student's t-test after analysis of variance. Probability values of P < 0.05 were considered to represent significant differences.
Formation of oligomeric and proto-fibriller states of Aβ40/42 monitored using AFM. While the monomeric state of Aβ40 showed very few small multimers, the oligomeric state was comprised of a good number of molecular associates of variable shape and size ( Figure  1 a and b) . The fibrillar state showed formation of long thread-like fibres along with oligomeric products (Figure  1 c) . This structure also showed intense emission in the ThT assay (shown later). The process of oligomerization was controlled so that the final state remained soluble. These soluble states are more toxic than the insoluble amyloid fibrils and are better targets for controlling amyloid depositions [25] [26] [27] [28] . Disaggregation of Aβ40 was quantified by ThT assay after incubation with variable concentrations of bromelain for 18 h. The bromelain was either functionally active or inactive or autodigested. The first two varieties contained intact bromelain. It was observed that all forms of bromelain were capable of destabilizing Aβ40 amyloid aggregates. Active and autodigested bromelain at 80 μg/ml disassembled the aggregates by 58-60% (Figure 1 d) . Interestingly, inactive bromelain also caused destabilization but to a lesser extent of nearly 40% (Figure 1 e) . These results collectively indicated that the proteolytic activity of bromelain was not of primary importance in this phenomenon. Rather the surface of the molecule or to be more precise, stretches of amino acid sequences of bromelain caused the disintegration of the amyloid aggregate.
Bromelain was digested with proteases similar to human digestive system to generate small peptides. Under these conditions, autodigestion of bromelain did not dominate. Aβ40 aggregates were degraded more efficiently by this pool of peptides as observed from the ThT assay. When incubated for 24 h at 37°C in the presence of 0-155 μM of the peptides, the extent of disaggregation approached near completion (Figure 2 a) . The time course of disaggregation was followed using as low as 5 μM of the peptides for 72 h, where an exponential rate of reaction was observed (Figure 2 b) . Under these conditions, nearly 90% of disaggregation was observed. The disaggregation was also verified by microscopic observations. TEM images showed the presence of fibriller structure of Aβ40 aggregate whereas the mesh-like structures were reduced to an agglomeration of oligomeric structures after 24 h of incubation with bromelain peptides (Figure 2 c, upper and lower panels). In Figure 2 c, the lower panel capture, an event where a large aggregate is being fragmented into smaller components. AFM profile of the destabilized aggregate showed that the rod-like fibriller structures were reduced to fragmented lumps ( Figure 2 d) . When the period of incubation was continued for 72-96 h, the oligomeric structures gradually disappeared.
When bromelain is hydrolysed by digestive enzymes, one cannot exclude the presence of some undigested proteins and large polypeptides among the products. Since inactive bromelain can destabilize amyloid aggregates and peptides of >700 Da cannot cross the blood brain barrier (BBB), very small peptides were separated from the peptide pool by Sephadex G-10 gel filtration chromatography. From the eluent, four fractions of 1 ml each were collected. These fractions correspond to the positions marked I-IV in Figure 3 a. Assuming that the fraction corresponding to void volume contained undigested bromelain and its large fragments, it was not considered. Rest of the collected fractions were rechromatographed under identical conditions (Figure 3 b, II-IV) . Assuming that the first two partially resolved peaks contain high M w proteins/peptides, rechromatograms showed greater abundance of small peptides from II to IV. These fractions supposedly contain peptides of very low M w . The mass distribution of the peak top of the third fractions of Figure 3 b (I-IV) was verified ( Figure 3 c-e) . In all cases, majority of the peptides detected were of M w <700 Da and thus are supposed to cross BBB as far as M w is concerned 29 . Towards prediction of peptides causing disaggregation, amino acid sequences of bromelain and Aβ42 were aligned using ClustalW2 software. Residues 16-22 (KLVFFAE) of Aβ42 form amyloid of their own and very likely form the core of the whole molecular fibrils 30 . This is the most aggregate-prone region of the Aβ peptide. This region shows strong homology with 168-174 (DSIIYPK) residues of bromelain. A tryptophan-rich sequence of bromelain KKWGAKWG (174-181) also shows significant homology next to the aggregate-prone region of Aβ42 (Figure 4 , upper panel, marked by bars). Tryptophan being one of the potent amino acids causing aggregation of Aβ amyloid, this stretch of peptide from bromelain may also interact with the Aβ conformers 31 . To ascertain the presence of such peptides within the peptide pool, the sequence of bromelain and masses of the digested peptides generated from mass spectrum were supplied as input in the interactive FindPept analysis software. The Figure 3 . a, Separation of peptides generated from bromelain after digestion with proteases by Sephadex G-10 gel filtration chromatography. b, II, III and IV are rechromatograms of the fractions marked II, III and IV in (a), under identical conditions of gel filtration as in (a). In all sets, the upper and lower tracings represent elution profiles followed at 220 and 280 nm respectively. c-e, ESI mass spectra of the third peaks of (b) (II-IV) monitored at 220 nm.
sequences of peptides generated from mass spectrometric analysis were searched from the sequence of stem bromelain. No peptide stretch within 168-174 residues of bromelain could be detected. Presence of free tryptophan of 205.06 Da from bromelain was observed. However, some tryptophan-rich peptides of identical M w of 461.25 Da were also detected. These were KWGA (175-178), WGAK (176-179), GAKW (177-180) and AKWG (178-181). Another tryptophan-rich peptide NPCGACWA (21-28, 821.31 Da) was also detected. It was not considered further due to its large size.
Once the peptides causing disaggregation were predicted and their presence in the peptide pool was confirmed from MS data, peptides of sequences KWGA, WGAK, GAKW and AKWG were synthesized. These peptides at 0.01-10.0 μM were incubated with Aβ40 aggregates for 15 days and disaggregation was followed by the ThT assay. Among these peptides, GAKW was the most potent where around 60% of disaggregation was achieved (Figure 4 a) . Other peptides showed disaggregation to variable extents. The effect of the mixture of these synthetic peptides at 1 and 10 μM on disaggregation of Aβ40 aggregates was also studied. Over 10 days, disaggregation varied from 50% to 70% (Figure 4 b) . No synergistic effect of the peptide mixture was observed. Overall, the extent of disaggregation was variable over time, probably because of complications arising from self-aggregation of the synthetic peptides.
Protection of cytotoxicity against 1 μM of Aβ42 aggregates on human neuroblastoma cells (SH-SY5Y) by 2-100 μM of bromelain-derived peptides was verified. Results showed that viability of the cells in the presence of toxic aggregates was limited to 28 ± 6%. Cell viability followed direct dependence on the concentration of the peptides, where maximum viability of 82 ± 7% could be achieved. No inconsistency in the results was observed ( Figure 5 ). Morphological patterns of the cells were monitored under phase contrast microscopy. Healthy cells without any treatment were evenly distributed, elongated or oval-shaped, where nuclei and processes were distinctly visible. Morphology of the Aβ oligomer-treated cells was different; the cells were non-uniformly clustered, round-shaped; nuclei were disintegrated and less prominent, and processes were short and indistinct. However, features of the visible cells treated with Aβ oligomer in the presence of bromelain-derived peptides were similar to those of healthy cells. Viability of cells in the presence of PBS or bromelain-derived peptides under identical conditions was similar, indicating that the peptides did not confer toxicity to the cells. Therefore, we demonstrate that preformed fibrils of Aβ40 are destabilized by stem bromelain or peptides derived from this enzyme. This study is confined to soluble pre-fibriller states of Aβ, which are the intermediates en route formation of β-amyloid plaques. These intermediate structures show higher toxicity to neuronal cells than the fibrils themselves [25] [26] [27] [28] . In this study, initial experiments were performed with Aβ40 because it is relatively cheap, aggregate-prone similar to Aβ42 and occurs in the blood.
The uptake of any compound in the brain is strictly regulated by the BBB 32 . The capacity of a peptide to cross the BBB and enter into the brain is dependent upon several compositional factors, including size, flexibility, conformation, sequence and hydrophobic/hydrophilic properties. Among these, molecular weight is a major factor 33 . Reviews often quote an absolute cut-off value of 450 Da for penetration into the BBB 29 . However, during inflammation as in the case of AD, when the integrity of BBB is lost, relatively bigger peptides may cross the barrier depending on the extent of damage. In this study, peptides smaller than 700 Da were separated from the pool of peptides generated from bromelain ( Figure 3 ). These small peptides could effectively destabilize Aβ aggregates up to 90% as observed from the ThT assay ( Figure 2 a and b) . TEM and AFM images confirmed these findings (Figure 2 c and d) . Holding the size restriction, probable peptides that are potent for Aβ disaggregation were identified by ClustalW2 and Interactive FindPept software analysis. Synthetic peptides having these sequences also showed disaggregation of Aβ40/42 (Figure 4 a and b) . Among these peptides, GAKW was the best. In AD, Aβ42 peptide deposits as fibrils in neuronal cells of the brain. The peptide pool from bromelain not only destabilized preformed aggregates of Aβ as observed from in vitro experiments, but also prevented growth of the oligomeric states/aggregates that are cytotoxic ( Figure 5 ).
To act efficiently as destabilizing Aβ aggregates, the peptides from bromelain should qualify the following criteria -the peptides should traverse the BBB, concentration of the peptides around the aggregates should be sufficient to destabilize the latter once administered to patients orally or intravenously, and animal model experiments should give a positive indication. These observations are unknown at present.
Protein aggregation is dynamic in nature, maintaining an equilibration between the oligomeric and monomeric states 34 . In the presence of antibody against the monomeric molecule, the strong binding between the monomeric state and the corresponding antibody shifts the equilibration towards dissociation of the aggregate 35 . Several small organic molecules of plant origin like curcumin 36 , resvitrol 37 , alpha-tocopherol 38 , caffeine 39 , etc. have different degrees of protection against fibril formation. Our recent observation indicates that peptides derived from fruit bromelain can efficiently dissociate preformed aggregates and also inhibit formation of aggregates from monomeric state of human insulin. It is proposed that binding of the peptides with monomeric insulin once dissociated from the aggregates causes irreversible conformational change, making them incapable of re-aggregation 40 . Dramatic improvement in cell viability as demonstrated in Figure 5 is suggestive of this hypothesis. The hypothesis is supported by the fact that synthetic peptides having the template of a toxin component of Russell's viper venom showed efficient disaggregation of Aβ amyloid 41 . A clearer mechanism of these processes is likely to be unveiled in near future.
